Cross-scale integration evaluation pulmonary nodule malignant risk prediction system

A technology for risk prediction and pulmonary nodules, applied in the biological field, can solve problems such as difficulty in predicting malignant risk of pulmonary nodules, and achieve the effect of simple expression level

Pending Publication Date: 2021-11-26
SOUTHEAST UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In view of the deficiencies of the existing technology, the purpose of the present disclosure is to provide a cross-scale integration of macroscopic CT images and microscopic serum exosomal miRNAs markers to evaluate the prediction model of pulmonary nodule malignant risk, which solves the problem of pulmonary nodule malignant risk in the prior art Difficult to predict problems

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cross-scale integration evaluation pulmonary nodule malignant risk prediction system
  • Cross-scale integration evaluation pulmonary nodule malignant risk prediction system
  • Cross-scale integration evaluation pulmonary nodule malignant risk prediction system

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Unless otherwise specified, the reagents and materials used in the following examples are all commercially available.

[0030] 1.1 Clinical sample collection:

[0031] The serum samples of 84 cases of malignant pulmonary nodules and 72 cases of benign pulmonary nodules in the control group were collected from Zhongda Hospital Affiliated to Southeast University from 2018 to 2020. All patients signed an informed consent to participate in the scientific research. Collect 5ml of non-anticoagulated peripheral blood, centrifuge at 3000rpm at 4°C for 10min, transfer the serum to 1.5ml EP tubes, and store at -80°C until use.

[0032] 1.2 Image feature collection:

[0033] Routine chest CT examinations were performed with one of the following multi-detector systems: Siemens Medicalsystems, Forchheim, Germany. The scanning parameters are as follows: 120kY, 100mAs, rotation speed 0.5s, collimation 16mm×0.75m, pitch 0.85.

[0034] The main information obtained includes: pulmona...

Embodiment 2

[0036] 2.1 Extraction of RNAs in microscopic serum exosomes:

[0037] Take peripheral blood from patients with malignant pulmonary nodules and patients with benign pulmonary nodules on an empty stomach in the morning, use non-anticoagulant tubes, centrifuge whole blood at 3000rpm at 4°C for 10min within 4h, collect serum and store in EP tubes without RNase, at -80°C Save for later. The supernatant was collected and centrifuged at 2000 g for 10 min at room temperature, 12000 g for 30 min, and filtered through a 0.22-μm filter to remove cell debris. Microscopic exosomes were purified by ultracentrifugation. Serum or cell supernatants were ultracentrifuged once at 100,000g for 70 minutes at 4°C to collect exosome-containing particles. All particles obtained were washed once with 11 ml of phosphate buffered saline and used for further experiments for each sample. According to the kit instructions, use 750 μl TRIzol LS kit (Invitrogen life technologies, USA) to extract total RNA...

Embodiment 3

[0058] 3.1 Establishment of lung cancer risk prediction model:

[0059] Taking the expression level of exosomal miRNAs of the normal control product as the standard, the expression level of exosomal miRNAs in the serum of patients with lung cancer is divided by this standard, so as to determine the expression ratio of the miRNAs profile of the patient relative to the normal person, and substitute the ratio into the following formula , to calculate the probability of malignant risk.

[0060] The model used univariate and multivariate logistic regression analysis to predict the incidence of early lung cancer step by step, and was tested by SPSS (version 22.0, SPSS Inc., IL, USA) and GraphPadPrism (version 8, CA, USA). In addition, through receiver operating characteristic curve (ROC), area under the curve (AUC) and classical matrix values ​​[sensitivity (SEN), specificity (SPE), positive predictive value (PPV), negative predictive value (NPV) and Accuracy (ACC)] validates the e...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a prediction system for cross-scale integration and evaluation of malignant risk of pulmonary nodules. The prediction system is composed of detection of serum exosome miRNAs markers hsa-miR-424-5p and hsa-miR-1271-5p, CT (Computed Tomography) imaging parameters and other clinical indexes. The model has the sensitivity of 90.91% and the specificity of 87.50% for evaluating the malignant risk of pulmonary nodules, can be used for early diagnosis of lung cancer, and has good clinical application value and wide application prospect.

Description

technical field [0001] The disclosure belongs to the field of biotechnology, and specifically relates to a cross-scale integrated evaluation system for predicting the malignant risk of pulmonary nodules Background technique [0002] Lung cancer is a serious threat to human health and is the leading cause of cancer-related deaths worldwide. In recent years, there are more than 600,000 new lung cancer patients in my country each year, and more than 500,000 dead patients, and the mortality rate is increasing year by year. Lung cancer is more common in late stages than in early stages, and has fewer survival rates and treatment options. The 5-year survival rate of patients with advanced lung cancer is <10%, while the early stage such as carcinoma in situ (CIS, Carcinoma in situ) and micro-invasive carcinoma (MIC, Micro-invasive carcinoma) are 100% curable. Therefore, the advancement of early detection technology for lung cancer is urgently needed, and accurate assessment of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G16B25/10G16B25/20G16B40/00
CPCG16B25/10G16B25/20G16B40/00
Inventor 张海军李尚沙马尔拜帕特尔靳激扬
Owner SOUTHEAST UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap